FDA
-
-
-
-
-
-
-
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
-
-
-
-
-
-
-
Savara receives EMA validation for MOLBREEVI application in rare lung disease
-
-
-
-
-
-
-
Savara Announces Participation in 2026 Citizens Life Sciences Conference
-
-
-
-
-
-
-
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
-
-
-
-
-
-
-
Savara receives European patent intent for MOLBREEVI formulation
-
-
-
-
-
-
-
Savara closes $149.5M public offering with full underwriter option
-
-
-
-
-
-
-
Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
-
324,694 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

